Publikationen in Zusammenarbeit mit Forschern von Boston Children's Hospital (51)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx (Nature, (2023), 616, 7957, (525-533), 10.1038/s41586-023-05783-5)

    Nature

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 6, pp. 1279-1292

  5. Global cross-sectional survey on neonatal pharmacologic sedation and analgesia practices and pain assessment tools: impact of the sociodemographic index (SDI)

    Pediatric Research

  6. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics

  7. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

  8. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

  9. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer, Vol. 5, Núm. 2, pp. 347-363

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 833-845

  5. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  6. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  7. The Cell Tracking Challenge: 10 years of objective benchmarking

    Nature Methods, Vol. 20, Núm. 7, pp. 1010-1020

  8. The Effects of COVID-19 Lockdown on the Sleep Quality of Children

    CHILDREN-BASEL, Vol. 10, Núm. 6

  9. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533

  10. The evolution of non-small cell lung cancer metastases in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 534-542

  11. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Nature, Vol. 616, Núm. 7957, pp. 553-562